Form 4: Stoke Therapeutics Executive Sells Shares to Cover Tax Obligations

A Stoke Therapeutics executive sold shares to cover tax liabilities related to the vesting of restricted stock units.

Summary

• Jonathan Allan, a Stoke Therapeutics executive, sold 9,696 shares of common stock on December 6, 2024.
• The sale was mandated by the issuer to satisfy tax withholding liabilities associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $12.7775.
• The transactions occurred at prices ranging from $11.93 to $13.46 per share.

Sentiment

Score: 5

Explanation: The document describes a routine transaction related to executive compensation and tax obligations, which is neither positive nor negative for the company's overall outlook.

Industry Context

Executive stock sales for tax purposes are a common occurrence in publicly traded companies, particularly around vesting periods for equity compensation.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a standard practice across the industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar tax-related sales.
• The price range of $11.93 to $13.46 is within the typical fluctuations seen in stock prices.

Stakeholder Impact

• The stock sale has a minimal impact on shareholders as it is a routine transaction.
• The sale does not affect the company's operations or financial health.

Key Dates

Keywords

Stoke Therapeutics, stock sale, executive, tax withholding, restricted stock units, share transaction